We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 28, 2020

T-DM1 in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastases

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastases: Exploratory Final Analysis of Cohort 1 From KAMILLA, a Single-Arm Phase IIIb Clinical Trial
Ann. Oncol 2020 Jul 04;[EPub Ahead of Print], F Montemurro, S Delaloge, CH Barrios, R Wuerstlein, A Anton, E Brain, T Hatschek, CM Kelly, C Peña-Murillo, M Yilmaz, M Donica, P Ellis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading